[HTML][HTML] Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023 - Springer
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
Challenges and new technologies in adoptive cell therapy.
P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023 - europepmc.org
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
[HTML][HTML] Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023 - ncbi.nlm.nih.gov
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
[HTML][HTML] Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - … of Hematology & …, 2023 - jhoonline.biomedcentral.com
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023 - search.proquest.com
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
Challenges and new technologies in adoptive cell therapy.
P Zhang, G Zhang, X Wan - Journal of Hematology & …, 2023 - search.ebscohost.com
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - Journal of hematology & …, 2023 - pubmed.ncbi.nlm.nih.gov
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
[引用][C] Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023 - europepmc.org
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
[HTML][HTML] Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - … of Hematology & …, 2023 - jhoonline.biomedcentral.com
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …